435327-40-5
435327-40-5
Chemical Structure
Avasopasem manganese
Synonym(s): GC-4419; M-40419
- CAS No.: 435327-40-5
- Formula:C21H35Cl2MnN5
- Molecular Weight:483.38
InChIKey: WXEMWBBXVXHEPU-NDOCQCNASA-L
SMILES: [Cl-][Mn+2]1234([N]5=C6C[NH]1[C@](CCCC7)([H])[C@@]7([H])[NH]2CC[NH]3[C@]8([H])[C@@](CCCC8)([H])[NH]4CC5=CC=C6)[Cl-]
Biological Activity: Avasopasem manganese (GC4419; M-40419) is a potent superoxide dismutase mimetic that rapidly and specifically converts O2*- to hydrogen peroxide (H2O2), arresting the initiation of this cascade. Avasopasem manganese can be used for the research of severe oral mucositis (SOM) and cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Avasopasem manganese | 96.07% | Avasopasem manganese (GC4419; M-40419) is a potent superoxide dismutase mimetic that rapidly and specifically converts O2*- to hydrogen peroxide (H2O2), arresting the initiation of this cascade. Avasopasem manganese can be used for the research of severe oral mucositis (SOM) and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Avasopasem manganese (Standard) | ≥98% | Avasopasem manganese (Standard) is the analytical standard of Avasopasem manganese (HY-109110). This product is intended for research and analytical applications. Avasopasem manganese (GC4419; M-40419) is a potent superoxide dismutase mimetic that rapidly and specifically converts O2*- to hydrogen peroxide (H2O2), arresting the initiation of this cascade. Avasopasem manganese can be used for the research of severe oral mucositis (SOM) and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Anderson CM, et al. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer [published correction appears in J Clin Oncol. 2020 Jan 20;38(3):288]. J Clin Oncol. 2019;37(34):3256-3265. [Content Brief]
